Neogenomics Inc. (NEO) Company Profile & Statistics

Neogenomics Inc.
NEO
(Nasdaq - US)
N/A
13.92
-1.30 (-8.54%)
in:usd•As of: Apr 30, 2024 10:58 UTC -4
Open
14.51
High
14.51
Low
13.83

About Neogenomics Inc.

CEO

Christopher M. Smith

Headquarters

9490 neogenomics way

fort myers, fl 33912, united states

Auditor

Deloitte & Touche LLP

Employees

2,100

Share Holders

645

Website

www.neogenomics.com

Industry

medical or nursing services

Sector

health services

Company Overview

NeoGenomics, Inc. is a high-complexity CLIA-certified clinical laboratory that specializes in cancer genetics diagnostic testing, the fastest growing segment of the laboratory industry. The company's testing services include cytogenetics, fluorescence in-situ hybridization, flow cytometry, morphology studies, anatomic pathology and molecular genetic testing. Headquartered in Fort Myers, FL, NeoGenomics has labs in Nashville, TN, Irvine, CA and Fort Myers and services the needs of pathologists, oncologists, urologists, hospitals and other reference laboratories throughout the United States.

Neogenomics Inc. Statistics

Valuation Measures

Market Capitalization ²	1.78B
Enterprise Value	1.97B
Enterprise Value/EBITDA (ttm)	-61.12
Price to Earnings Ratio (ttm)	N/A
Price to Book (mrq)	1.91
Price to Sales (ttm)	3.05
Price to Cash (ytd)	50.08

Profitability

Gross Margin (ttm)	41.29%
Operating Margin (ttm)	-6.67%
Profit Margin (ttm)	-15.10%
Return on Equity (ttm)	-4.13%
Return on Invested Capital (ttm)	-5.88%
Return on Assets (ttm)	-2.33%

Income Statement

Revenue (ttm)	591.64M
Revenue Per Share (ttm)	4.64
Gross Profit (ttm)	244.60M
EBITDA (ttm)³	-32.28M
Net Income Avi to Common (ttm)	-87.97M
Diluted EPS (ttm)	-0.70

Share Statistics

Beta (5Y Monthly)	1.10
52-Week Change	-5.43%
S&P500 52-Week Change	25.82%
S&P500 Member	No
Stock Optionable	Yes
Total Shares Outstanding ¹	127.61M
Dividend Yield	0.00%
Float ⁴	126.01M
% Held by Insiders	1.30%
% Held by Institutions	98.50%

Balance Sheet

Total Cash (mrq)	415.20M
Total Cash Per Share (mrq)	3.25
Total Debt (mrq)	538.20M
Total Debt/Equity (mrq)	57.16%
Current Ratio (mrq)	6.20%
Quick Ratio (mrq)	5.95%
Book Value Per Share (mrq)	7.39

Cash Flow

Operating Cash Flow Per Share (ytd)	-0.02
Free Cash Flow (ytd)	-30.70M

Table Key

mrq = Most Recent Quarter

ttm = Trailing Twelve Months

ytd = Year To Date

Footnotes

Data provided by Zacks Investment Research or calculated by FXEmpire. Stock price provided by Xignite. All numbers are rounded to the closest decimal.

¹ Total Shares outstanding is taken from the most recently filed quarterly or annual report.

² Market Cap is calculated using total shares outstanding and the most recent share price.

³ EBITDA is calculated using methodology that may differ from that used by a company in its reporting.

⁴ The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.

Neogenomics Inc.

Trade With A Regulated Broker